← All trials
NCT05614817
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Aug 31, 2024
- Completion date
- Jul 31, 2025
- First posted
- Nov 14, 2022
- Last posted
- Nov 14, 2022
- Enrollment
- 450
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Connect BiopharmaceuticalsLead sponsor
- Suzhou Connect BiopharmaceuticalsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.